<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328821</url>
  </required_header>
  <id_info>
    <org_study_id>CP505.1001 CTP-499</org_study_id>
    <nct_id>NCT01328821</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose, Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability Study of CTP-499 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concert Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concert Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and pharmacokinetics of
      CTP-499 following single dose administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, single ascending dose administration study of four doses of CTP-499.
      Following dosing safety and tolerability will be assessed. Blood and urine samples will be
      taken for pharmacokinetics (PK) and bioavailability. Safety assessments will include
      monitoring of adverse events, vital signs (blood pressure, pulse rate, respiratory rate and
      oral temperature), clinical laboratory findings, 12-lead ECGs, and physical examination
      findings.

      The plasma concentration time data for CTP-499 and its metabolites will be analyzed using
      noncompartmental methods. Actual dosing and sampling times will be used for analysis. The
      primary pharmacokinetics parameters are: Cmax, Tmax, T1/2, AUClast and AUCinf for plasma;
      relative bioavailability; and Ae and CLr for urine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess safety and tolerability of CTP-499</measure>
    <time_frame>5 days</time_frame>
    <description>Assessments will include monitoring of adverse events, vital signs (blood pressure, pulse rate, respiratory rate and oral temperature), clinical laboratory findings, 12 lead ECGs, and physical examination findings. Safety data will be summarized using descriptive statistics for all subjects who receive at least 1 dose. Adverse events will be summarized by frequency. Abnormal laboratory and physical exam findings will be summarized by dose and treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess Pharmacokinetics, Pharmacodynamics and relative bioavailability</measure>
    <time_frame>2 days</time_frame>
    <description>Pharmacokinetics: individual and mean concentration time profiles will be presented graphically. Alll PK parameters will be summarized by dose group using descriptive statistics (eg n, arithmetic mean, SD, geometric mean, median, CV). Relative bioavailability will be estimated using the geometric mean values of dose normalized AUC for each dose.
Pharmacodynamics: From the 12 lead ECG data, VR, PR, QRS, QT, QTcF andd QTcB will be reported for each time point and summarized using descriptive statistics. Mean temporal profiles for 12 lead ECG and vital signs will be presented graphically.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single ascending dose administration of four doses of CTP-499 as tablets under fasting condition.
8 subjects per dose group will be enrolled with a 3:1 randomization of active drug to placebo.
Dose levels: 600mg -&gt; 1200mg -&gt; 1800mg -&gt; 2400mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part B will consist of a single 400 mg dose of an immediate release capsule of CTP-499 administered under fasting conditions. In Part B 6 subjects will be enrolled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-499</intervention_name>
    <description>600 mg, 1200 mg, 1800 mg and 2400 mg</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-499</intervention_name>
    <description>400 mg immediate release capsule</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

          -  ages 18 to 55 years old

          -  nonsmokers

          -  BMI of 18 to 30 kg/m2

        Exclusion Criteria:

          -  Significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine,
             hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic,
             lipid metabolism disorders of drug hypersensitivity

          -  Systolic Blood pressure &lt; 90 or &gt; 140, diastolic bp &gt; 90
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Tracey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Frontage Clinical Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Frontage</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.concertpharma.com</url>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <last_update_submitted>October 25, 2011</last_update_submitted>
  <last_update_submitted_qc>October 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

